Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma

被引：60

作者：

Chen, Chang-Yu ^{[1
,2
]}

Lin, Yung-Song ^{[3
,4
]}

Chen, Chien-Ho ^{[1
]}

Chen, Yin-Ju ^{[5
,6
,7
,8
]}

机构：

[1] Taipei Med Univ, Coll Med Sci & Technol, Sch Med Lab Sci & Biotechnol, 250 Wu Xing St, Taipei 11031, Taiwan

[2] Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo, Japan

[3] Taipei Med Univ, Coll Med, Sch Med, Dept Otolaryngol, Taipei, Taiwan

[4] Chi Mei Med Ctr, Dept Otolaryngol, Tainan, Taiwan

[5] Taipei Med Univ Hosp, Dept Radiat Oncol, Taipei, Taiwan

[6] Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan

[7] Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei, Taiwan

[8] Taipei Med Univ, Coll Biomed Engn, Sch Biomed Engn, Taipei, Taiwan

来源：

JOURNAL OF BIOMEDICAL SCIENCE | 2018年 / 25卷

关键词：

Annexin A2 (ANXA2); Nasopharyngeal carcinoma (NPC); Cancer progression; Therapeutic resistance; GROWTH-FACTOR RECEPTOR; STEM-LIKE CELLS; DENDRITIC CELLS; DC-SIGN; BREAST-CANCER; CHROMOSOMAL INSTABILITY; PROGNOSTIC-SIGNIFICANCE; CYTOKINE PRODUCTION; ACCESSORY CELLS; DRUG-RESISTANCE;

D O I：

10.1186/s12929-018-0430-8

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Nasopharyngeal carcinoma (NPC) is a head and neck cancer with poor clinical outcomes and insufficient treatments in Southeast Asian populations. Although concurrent chemoradiotherapy has improved recovery rates of patients, poor overall survival and low efficacy are still critical problems. To improve the therapeutic efficacy, we focused on a tumor-associated protein called Annexin A2 (ANXA2). This review summarizes the mechanisms by which ANXA2 promotes cancer progression (e.g., proliferation, migration, the epithelial-mesenchymal transition, invasion, and cancer stem cell formation) and therapeutic resistance (e.g., radiotherapy, chemotherapy, and immunotherapy). These mechanisms gave us a deeper understanding of the molecular aspects of cancer progression, and further provided us with a great opportunity to overcome therapeutic resistance of NPC and other cancers with high ANXA2 expression by developing this prospective ANXA2-targeted therapy.

引用

页数：10

共 113 条

[31]

Gazzinelli RT, 1996, J IMMUNOL, V157, P798

[32] DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells [J].